Elix CEO Aims to Lead Japan’s AI Drug Discovery Field

In the United States and Europe, interest in the potential of artificial intelligence to transform different aspects of the life sciences industry is at an all-time high.

Much of the attention has been given to the potential of a machine learning-based algorithmic approach to drug discovery.

The charge was led by companies such as the French company Iktos, the British company Exscientia (Nasdaq: EXAI) and BenevolentAI, and American companies such as Seismic Therapeutic,…

This article is accessible to registered users, to continue reading, please register for free. A free trial will give you access to exclusive features, interviews, summaries and commentary from the sharpest minds in the pharma and biotech space for one week. If you are already a registered user, please login. If your trial period is over, you can register here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science journalists.
• Receive The Pharma Letter daily newsletter, free forever.

Become a subscriber

• Unfettered access to top pharmaceutical and biotechnology industry news, commentary and analysis.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patent and legal, executive appointments, business strategy and financial results.
• Daily roundup of key events in pharma and biotechnology.
• In-depth monthly briefings on board appointments and M&A news.
• Choose between an economical annual plan or a flexible monthly subscription.